Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 55154-0284

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 55154-0284). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

80mg Bag Label (Fbd1c5da 67fb 4412 Acb5 4d4c74a43654 00)

Atorvastatin Calcium Tablets USP 80 mg film-coated tablets package label. The label shows packaging for 6 tablets, noting the tablets are white to off-white, oval, and debossed with '80' on one side. It includes storage instructions, warning the package is not child-resistant and is for institutional use only. The label lists Mylan Pharmaceuticals as manufacturer and Cardinal Health as distributor.*

FDA Label Image

Atorvastatin Calcium Structural Formula (Image 01)

Chemical structure of atorvastatin calcium trihydrate, showing the detailed molecular arrangement including fluorophenyl, phenyl, and hydroxy groups within the compound.*

FDA Label Image

Figure 1: Effect Of Atorvastatin Calcium Tablets 10 mg/day On Cumulative Incidence Of Non-fatal Myocardial Infarction Or Coronary Heart Disease Death (in Ascot-lla) (Image 06)

A line graph depicting cumulative incidence percentages over a period of 3.5 years, comparing Atorvastatin and placebo groups. Two lines are shown: a solid line for Atorvastatin and a dashed line for placebo, with incidence increasing over time. The graph includes a hazard ratio (HR=0.64 with confidence interval 0.50-0.83) and a p-value of 0.0005.*

FDA Label Image

Figure 2: Effect Of Atorvastatin Calcium Tablets 10 mg/day On Time To Occurrence Of Major Cardiovascular Event (myocardial Infarction, Acute Chd Death, Unstable Angina, Coronary Revascularization, Or (Image 07)

A line graph showing cumulative hazard (%) over time in years to first primary endpoint through four years of follow-up. The chart compares placebo and atorvastatin treatments, with atorvastatin showing a lower cumulative hazard than placebo. Hazard ratio and p-value are displayed on the graph.*

FDA Label Image

Figure 3: Effect Of Atorvastatin Calcium Tablets 80 mg/day Vs. 10 mg/day On Time To Occurrence Of Major Cardiovascular Events (tnt) (Image 08)

A line graph comparing the percentage of subjects experiencing a major cardiovascular event over time (up to 5 years) for Atorvastatin 10 mg and 80 mg doses. The x-axis represents time in years, and the y-axis shows the percentage of subjects with events. The 80 mg dose line is lower, indicating fewer events, with a hazard ratio of 0.78 (95% CI 0.69-0.89) and P=0.0002.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.